BRCA1 and neoplasm: Beyond BRCA1/2 PVs in the germline, the identification of somatic PVs in the tumor has become increasingly important, predominantly driven by promising results of poly-(ADP-ribose)-polymerase (PARP) inhibitors in EOC patients [1–3].